The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells
- PMID: 11136299
- PMCID: PMC2015020
- DOI: 10.1046/j.1365-2125.2000.00302.x
The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells
Abstract
Aims: Lamivudine (3TC, 2'-deoxy-3'-thiacytidine) requires intracellular metabolism to its active 5'-triphosphate, 3TC-5'-triphosphate (3TCTP), to inhibit the replication of hepatitis B virus (HBV). We have investigated the activation of 3TC, in the presence and absence of a range of compounds, in HepG2 cells. The intracellular levels of the endogenous competitor of 3TCTP, 2'-deoxycytidine-5'-triphosphate (dCTP), were also determined and 3TCTP/dCTP ratios calculated.
Methods: The effects of a number of compounds on 3TC (3H; 1 microM) phosphorylation were investigated by radiometric h.p.l.c. dCTP levels were determined using a template primer extension assay. 3TCTP/dCTP ratios were calculated from these results.
Results: The phosphorylation of 3TC was significantly increased in the presence of either hydroxyurea (HU), methotrexate (MTX), or fludarabine (FLU). For example, at 100 microM HU, control 3TCTP levels were increased to 361% of control, whereas at 100 microM FLU, control 3TCTP levels were increased to 155%. dCTP pools were significantly reduced in the presence of HU and FLU, at 100 microM concentrations only. However, for all the above three compounds investigated, the ratio of 3TCTP/dCTP was favourably enhanced (e.g. at 1 microM MTX, 255% of control). Neither ganciclovir (GCV), lobucavir (LCV), penciclovir (PCV), adefovir dipivoxil (ADV), nor foscarnet (FOS) had any significant effects on 3TC phosphorylation or dCTP pools.
Conclusions: These results suggest that the activity of 3TC may be potentiated when combined with one of the modulators studied. The lack of an interaction between 3TC and the other anti-HBV agents is reassuring. These in vitro studies can be used as an initial screen to examine potential interactions at the phosphorylation level.
Figures
Similar articles
-
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).J Virol. 2001 May;75(10):4771-9. doi: 10.1128/JVI.75.10.4771-4779.2001. J Virol. 2001. PMID: 11312349 Free PMC article.
-
Lamivudine (3TC) phosphorylation and drug interactions in vitro.Biochem Pharmacol. 1997 Sep 1;54(5):589-95. doi: 10.1016/s0006-2952(97)00189-5. Biochem Pharmacol. 1997. PMID: 9337075
-
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.Clin Pharmacokinet. 2004;43(12):823-32. doi: 10.2165/00003088-200443120-00004. Clin Pharmacokinet. 2004. PMID: 15355127 Clinical Trial.
-
Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.Biochim Biophys Acta. 2002 Jul 18;1587(2-3):296-9. doi: 10.1016/s0925-4439(02)00092-3. Biochim Biophys Acta. 2002. PMID: 12084471 Review.
-
Clinical pharmacokinetics of lamivudine.Clin Pharmacokinet. 1999 Jan;36(1):41-66. doi: 10.2165/00003088-199936010-00004. Clin Pharmacokinet. 1999. PMID: 9989342 Review.
Cited by
-
Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.Antimicrob Agents Chemother. 2005 Oct;49(10):3997-4008. doi: 10.1128/AAC.49.10.3997-4008.2005. Antimicrob Agents Chemother. 2005. PMID: 16189072 Free PMC article. Clinical Trial.
-
Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerases.Chem Res Toxicol. 2012 Jan 13;25(1):225-33. doi: 10.1021/tx200458s. Epub 2011 Dec 16. Chem Res Toxicol. 2012. PMID: 22132702 Free PMC article.
-
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Antimicrob Agents Chemother. 2002 Aug;46(8):2525-32. doi: 10.1128/AAC.46.8.2525-2532.2002. Antimicrob Agents Chemother. 2002. PMID: 12121928 Free PMC article.
-
Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids.Mol Pharmacol. 2015;87(3):430-41. doi: 10.1124/mol.114.096784. Epub 2014 Dec 9. Mol Pharmacol. 2015. PMID: 25492813 Free PMC article.
-
Liver Damage During Treatment with Reverse-Transcriptase Inhibitors in HIV Patients.Curr Health Sci J. 2024 Apr-Jun;50(2):181-197. doi: 10.12865/CHSJ.50.02.03. Epub 2024 Jun 30. Curr Health Sci J. 2024. PMID: 39371070 Free PMC article. Review.
References
-
- Beasley RP, Hwang L-Y, Ling C-C, Chien C-S. Hepatocellular carcinoma and hepatitis B virus. Lancet. 1981;ii:1129–1133. - PubMed
-
- Weissberg JI, Andres LL, Smith CL. Survival in chronic hepatitis B. an analysis of 379 patients. Ann Intern Med. 1984;101:613–616. - PubMed
-
- Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem. 1987;56:651–693. - PubMed
-
- Wang G-H, Seegar C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell. 1992;71:663–670. - PubMed
-
- Davis GL, Hoofnagle JH. Interferon in viral hepatitis: role in pathogenesis and treatment. Hepatology. 1986;6:1038–1041. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources